INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR RESEARCH & DEVELOPMENT
SJIF 2019: 5.222 2020: 5.552 2021: 5.637 2022:5.479 2023:6.563 2024: 7,805
eISSN :2394-6334 https://www.ijmrd.in/index.php/imjrd Volume 12, issue 06 (2025)

HORMONAL INFLUENCE ON BREAST CANCER DEVELOPMENT AND PROGRESSION: MOLECULAR INSIGHTS AND THERAPEUTIC ADVANCES

5th year students of the Faculty of Pediatrics of Samarkand State Medical University

Shafkatilloyeva Kamola G'anijon kizi,

Abdusalomova O'g'iloy Sanjar kizi,

Eshmamatova Fayyoza Boymamatovna,

3th year students of the Faculty of Pediatrics of Samarkand State Medical University

Xosilova Ug'iloy Ravshan kizi,

Elmurodova Noila Husniddin kizi

Abstract: Breast cancer is the most commonly diagnosed malignancy among women globally, with hormonal factors playing a pivotal role in its pathogenesis and progression. Estrogen and progesterone, the primary female sex hormones, are deeply implicated in tumor development through their interaction with nuclear hormone receptors and subsequent gene regulation. This article explores the molecular mechanisms by which hormones influence breast cancer initiation and evolution. It also reviews current hormonal therapies, including selective estrogen receptor modulators (SERMs), aromatase inhibitors, and emerging targeted approaches. Moreover, recent statistics, clinical trial outcomes, and global treatment disparities are examined to present a comprehensive understanding of hormone-driven breast cancer management.

Keywords: Breast cancer, estrogen, progesterone, hormone receptors, SERMs, aromatase inhibitors, hormonal therapy, molecular oncology, targeted treatment, endocrine resistance.

Introduction: Breast cancer remains the leading cause of cancer-related death among women, accounting for nearly 15% of all cancer deaths in females worldwide. According to the World Health Organization (WHO), more than 2.3 million women were diagnosed with breast cancer in 2022, with approximately 685,000 deaths globally. A significant proportion — over 70% — of breast cancer cases are hormone receptor-positive (HR+), indicating that the tumors grow in response to estrogen and/or progesterone signaling.

Hormones, especially estrogen and progesterone, are central to breast development, cellular proliferation, and tissue homeostasis. However, dysregulation of hormonal pathways can lead to uncontrolled cellular growth, genomic instability, and ultimately malignant transformation. This article delves into the intricate hormonal mechanisms that fuel breast cancer and outlines therapeutic strategies that target these pathways for better patient outcomes.

Hormonal Pathways in Breast Cancer Development.

Estrogen and progesterone exert their effects through binding to their respective receptors — estrogen receptor (ER) and progesterone receptor (PR) — located within the nuclei of breast epithelial cells. Upon binding, these receptors act as transcription factors, regulating genes associated with cell growth, survival, and differentiation.

In hormone-sensitive breast cancers, increased estrogen exposure — whether endogenous (early menarche, late menopause) or exogenous (hormone replacement therapy, oral contraceptives) — is associated with heightened cancer risk. Estrogen promotes proliferation by upregulating

cyclin D1, c-myc, and BCL-2, and downregulating tumor suppressors like p53. Furthermore, estrogen can induce mutations through oxidative stress and generate a pro-inflammatory microenvironment favorable to tumor development.

Progesterone, although more controversial in its role, also modulates cellular proliferation, particularly in the luteal phase. Recent evidence suggests that progesterone can either promote or inhibit tumor progression depending on the receptor isoform expression (PR-A vs PR-B) and the presence of co-regulatory proteins.

Molecular Subtypes of Hormone-Responsive Breast Cancer

Breast cancer is a heterogeneous disease with distinct molecular subtypes:

Luminal A: ER+ and/or PR+, HER2-, low Ki-67 — most hormone-responsive, better prognosis.

Luminal B: ER+ and/or PR+, HER2±, high Ki-67 — more aggressive, partial hormone response.

HER2-enriched: ER-/PR-, HER2+ — less hormone-sensitive, treated with HER2-targeted therapy.

Triple-negative: ER-/PR-/HER2- — not hormone-driven, requires chemotherapy or immunotherapy.

Luminal A and B subtypes, which constitute over 60% of breast cancer cases, are the primary targets of hormonal therapies.

Current Hormonal Therapies and Mechanisms

Hormonal therapy is the mainstay treatment for HR+ breast cancer. These therapies either block hormone receptors or reduce hormone production. The main categories include:

1. Selective Estrogen Receptor Modulators (SERMs)

Tamoxifen, the most well-known SERM, binds to estrogen receptors and inhibits transcriptional activation in breast tissue. It reduces the risk of recurrence and mortality by over 30% when used for 5–10 years post-surgery in ER+ patients.

2. Aromatase Inhibitors (AIs)

Drugs like anastrozole, letrozole, and exemestane block the aromatase enzyme that converts androgens to estrogen, effectively lowering estrogen levels in postmenopausal women. AIs are now preferred over tamoxifen in many postmenopausal settings due to better disease-free survival rates.

3. Selective Estrogen Receptor Degraders (SERDs)

Fulvestrant is a SERD that not only blocks the ER but also accelerates its degradation. It is effective in advanced or metastatic HR+ breast cancer, particularly after resistance to first-line hormonal agents.

4. CDK4/6 Inhibitors (Combination Therapy)

Newer strategies combine hormonal therapy with cyclin-dependent kinase inhibitors (e.g., palbociclib, ribociclib) to prevent cell cycle progression. These

combinations have demonstrated a 40–60% improvement in progression-free survival.

Endocrine Resistance and Its Management

Despite initial responsiveness, nearly 40% of HR+ breast cancers eventually develop resistance to hormonal therapy. Mechanisms include:

ER gene mutations (e.g., ESR1 mutations)

Upregulation of alternative growth pathways (e.g., PI3K/AKT/mTOR)

Epigenetic changes affecting ER expression

To combat resistance, dual blockade strategies are employed. For instance, adding an mTOR inhibitor (everolimus) or PI3K inhibitor (alpelisib) to endocrine therapy has shown improved outcomes in resistant cases.

Clinical Outcomes and Global Statistics

Tamoxifen use for 5 years reduces recurrence risk by 47% in premenopausal women (EBCTCG meta-analysis, 2021)

Aromatase inhibitors offer a 30% reduction in recurrence risk compared to tamoxifen in postmenopausal women CDK4/6 inhibitors + hormonal therapy have extended median progression-free survival to 24–28 months vs 14 months with hormonal therapy alone.

In high-income countries, 5-year survival for HR+ breast cancer exceeds 90%, while in low-income settings, it remains below 60% due to delayed diagnosis and poor access to hormonal therapies

Future Directions in Hormone-Based Therapies

Precision medicine is reshaping hormonal therapy. Genomic assays (e.g., Oncotype DX, MammaPrint) help predict recurrence risk and guide therapy decisions. Trials are also exploring:

Oral SERDs (e.g., elacestrant) with better bioavailability

Immunotherapy combined with hormonal agents.

Vaccines targeting hormone receptor-related antigens.

Epigenetic modulators to reverse ER silencing.

AI-based modeling and big data analytics are increasingly used to personalize hormonal treatment regimens and predict resistance patterns.

Conclusion

Hormonal influence on breast cancer is profound, both as a causative factor and as a therapeutic target. Understanding the molecular pathways underlying hormone-driven tumorigenesis has led to significant advances in treatment, particularly for ER+/PR+ breast cancers. The combination of classic endocrine therapy with modern targeted agents is improving survival rates and quality of life for millions of women worldwide. However, disparities in access, emerging resistance, and tumor heterogeneity continue to challenge clinicians and researchers. The future lies in precision oncology, where hormonal therapy is tailored to each patient's unique molecular profile, ensuring maximum efficacy and minimal toxicity.

References:Uzbek Medical Sources:

1. Khodjayeva G.M., Saidova R.N. (2023). Ayollarda ko‘krak bezi saratoni: gormonlar va davolash yondashuvlari. Tashkent: O‘zbekiston onkologiya markazi nashriyoti.

2. Boboyeva Z.M. (2022). Endokrin onkologiyaning zamonaviy yondashuvlari. Buxoro: BuxDTU ilmiy jurnali.

International Sources:

3. World Health Organization (2023). Breast Cancer Fact Sheet. Geneva: WHO Press.

4. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2021). Long-term effects of endocrine therapy of breast cancer. The Lancet, 397(10287), 1445–1458.

5. Finn R.S., et al. (2016). Palbociclib and Letrozole in Advanced Breast Cancer. New England Journal of Medicine, 375(20), 1925–1936.

6. Gnant M., et al. (2017). Everolimus in hormone receptor-positive advanced breast cancer. The Lancet Oncology, 18(7), 963–975.

7. Osborne C.K., Schiff R. (2011). Mechanisms of endocrine resistance in breast cancer. Annual Review of Medicine, 62, 233–247.

8. Ellis M.J., et al. (2022). ESR1 mutations and hormonal therapy resistance. Cancer Discovery, 12(3), 624–635.